Mereo Biopharma Group Plc (MREO) Stock Forecast & Price Target

Compare

830 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MREO Analyst Ratings

Strong Buy

6 Buy

2 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Mereo

Biopharma Group Plc

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MREO Stock 12 Month Forecast

Average Price Target

$1.75

▲(207.02% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Mereo Biopharma Group Plc in the last 3 months. The average price target is $1.75 with a high forecast of $3.00 and a low forecast of $0.50. The average price target represents a 207.02% change from the last price of $0.57.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","-1":"-$1","0.25":"$0.25","1.5":"$1.5","2.75":"$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.42,0.6184615384615384,0.8169230769230769,1.0153846153846153,1.2138461538461538,1.4123076923076923,1.6107692307692307,1.8092307692307692,2.0076923076923077,2.206153846153846,2.4046153846153846,2.603076923076923,2.8015384615384615,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.42,0.5223076923076923,0.6246153846153846,0.7269230769230769,0.8292307692307692,0.9315384615384614,1.0338461538461539,1.136153846153846,1.2384615384615385,1.3407692307692307,1.443076923076923,1.5453846153846154,1.6476923076923076,{"y":1.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.42,0.42615384615384616,0.4323076923076923,0.43846153846153846,0.4446153846153846,0.45076923076923076,0.45692307692307693,0.46307692307692305,0.46923076923076923,0.4753846153846154,0.4815384615384615,0.4876923076923077,0.4938461538461538,{"y":0.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.01,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.17,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.76,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.77,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.42,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$3.00

Average Price Target$1.75

Lowest Price Target$0.50

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gil Blum

Needham

$5→$3

Buy

426.32%

Upside

Reiterated

01/13/26

Analysts Conflicted on These Healthcare Names: Apellis Pharmaceuticals (NASDAQ: APLS), Sarepta Therapeutics (NASDAQ: SRPT) and Mereo Biopharma Group Plc (NASDAQ: MREO)

Kristen Kluska

Cantor Fitzgerald

Buy

426.32%

Upside

Reiterated

01/12/26

Cantor Fitzgerald Sticks to Their Buy Rating for Mereo Biopharma Group Plc (MREO)

Cory Jubinville, PhD

LifeSci Capital

Hold

―

Reiterated

01/12/26

Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (NASDAQ: IRTC), Butterfly Network (NYSE: BFLY) and Mereo Biopharma Group Plc (NASDAQ: MREO)

Joseph Schwartz

Leerink Partners

$8→$2

Buy

250.88%

Upside

Reiterated

12/31/25

Mereo Biopharma Group Plc (MREO) Receives a Buy from Leerink Partners

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$7→$0.5

Hold

-12.28%

Downside

Downgraded

12/29/25

Jefferies downgrades Mereo Biopharma Group Plc (MREO) to a Hold

Julian Harrison

BTIG

$6→$1

Buy

75.44%

Upside

Reiterated

12/29/25

Mereo BioPharma price target lowered to $1 from $6 at BTIGMereo BioPharma price target lowered to $1 from $6 at BTIG

Priyanka Grover

J.P. Morgan

Buy

―

Reiterated

12/29/25

Mereo Biopharma: Depressed Valuation and Cost Controls Offset Setrusumab Trial Setback, Supporting Buy Rating on Upcoming Catalysts

Jack Allen

Robert W. Baird

$8→$1

Buy

75.44%

Upside

Reiterated

12/29/25

Mereo BioPharma price target lowered to $1, 'Fresh Pick' removed at BairdMereo BioPharma price target lowered to $1, 'Fresh Pick' removed at Baird

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

Buy

1128.07%

Upside

Initiated

03/27/25

Mereo Biopharma ADRs Rated New Overweight at JPMorgan; PT $7

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gil Blum

Needham

$5→$3

Buy

426.32%

Upside

Reiterated

01/13/26

Analysts Conflicted on These Healthcare Names: Apellis Pharmaceuticals (NASDAQ: APLS), Sarepta Therapeutics (NASDAQ: SRPT) and Mereo Biopharma Group Plc (NASDAQ: MREO)

Kristen Kluska

Cantor Fitzgerald

Buy

426.32%

Upside

Reiterated

01/12/26

Cantor Fitzgerald Sticks to Their Buy Rating for Mereo Biopharma Group Plc (MREO)

Cory Jubinville, PhD

LifeSci Capital

Hold

―

Reiterated

01/12/26

Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (NASDAQ: IRTC), Butterfly Network (NYSE: BFLY) and Mereo Biopharma Group Plc (NASDAQ: MREO)

Joseph Schwartz

Leerink Partners

$8→$2

Buy

250.88%

Upside

Reiterated

12/31/25

Mereo Biopharma Group Plc (MREO) Receives a Buy from Leerink Partners

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$7→$0.5

Hold

-12.28%

Downside

Downgraded

12/29/25

Jefferies downgrades Mereo Biopharma Group Plc (MREO) to a Hold

Julian Harrison

BTIG

$6→$1

Buy

75.44%

Upside

Reiterated

12/29/25

Mereo BioPharma price target lowered to $1 from $6 at BTIGMereo BioPharma price target lowered to $1 from $6 at BTIG

Priyanka Grover

J.P. Morgan

Buy

―

Reiterated

12/29/25

Mereo Biopharma: Depressed Valuation and Cost Controls Offset Setrusumab Trial Setback, Supporting Buy Rating on Upcoming Catalysts

Jack Allen

Robert W. Baird

$8→$1

Buy

75.44%

Upside

Reiterated

12/29/25

Mereo BioPharma price target lowered to $1, 'Fresh Pick' removed at BairdMereo BioPharma price target lowered to $1, 'Fresh Pick' removed at Baird

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

Buy

1128.07%

Upside

Initiated

03/27/25

Mereo Biopharma ADRs Rated New Overweight at JPMorgan; PT $7

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Mereo Biopharma Group Plc

3 Months

xxx

Success Rate

13/16 ratings generated profit

Average Return

+17.84%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 81.25% of your transactions generating a profit, with an average return of +17.84% per trade.

1 Year

Joseph SchwartzLeerink Partners

Success Rate

8/16 ratings generated profit

Average Return

+39.14%

reiterated a buy rating 15 days ago

Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +39.14% per trade.

2 Years

xxx

Success Rate

7/16 ratings generated profit

Average Return

+6.11%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 43.75% of your transactions generating a profit, with an average return of +6.11% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MREO Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MREO has received 11 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. MREO average Analyst price target in the past 3 months is 1.75.

Each month's total comprises the sum of three months' worth of ratings.

MREO Financial Forecast

MREO Earnings Forecast

Next quarter’s earnings estimate for MREO is -$0.01 with a range of -$0.02 to -$0.01. The previous quarter’s EPS was -$0.01. MREO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MREO has Performed in-line its overall industry.

MREO Sales Forecast

Next quarter’s sales forecast for MREO is $23.33M with a range of $0.00 to $35.00M. The previous quarter’s sales results were $0.00. MREO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MREO has Performed in-line its overall industry.

MREO Stock Forecast FAQ

What is MREO’s average 12-month price target, according to analysts?

Based on analyst ratings, Mereo Biopharma’s 12-month average price target is 1.75.

What is MREO’s upside potential, based on the analysts’ average price target?

Mereo Biopharma has 207.02% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MREO a Buy, Sell or Hold?

Mereo Biopharma has a consensus rating of Strong Buy which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings.

What is Mereo Biopharma’s price target?

The average price target for Mereo Biopharma is 1.75. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $3.00 ,the lowest forecast is $0.50. The average price target represents 207.02% Increase from the current price of $0.57.

What do analysts say about Mereo Biopharma?

Mereo Biopharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of MREO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Mereo Biopharma Group Plc (MREO) Stock Forecast & Price Target

MREO Analyst Ratings

MREO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Mereo Biopharma Group Plc

MREO Analyst Recommendation Trends

MREO Financial Forecast

MREO Earnings Forecast

MREO Sales Forecast

MREO Stock Forecast FAQ

Detailed List of Analyst Forecasts